A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
Condition(s):Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck CancerLast Updated:May 21, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck CancerLast Updated:May 21, 2020Unknown status
Condition(s):Non-small Cell Lung CancerLast Updated:February 7, 2018Terminated
Condition(s):Advanced Nonhematologic MalignanciesLast Updated:October 30, 2019Completed
Condition(s):Metastatic Solid TumorsLast Updated:March 9, 2017Completed
Condition(s):Advanced Solid Tumor; PIK3CA Mutation; PTEN Loss of Function MutationLast Updated:February 13, 2024Active, not recruiting
Condition(s):Clear-cell Metastatic Renal Cell CarcinomaLast Updated:November 19, 2021Completed
Condition(s):Endometrial NeoplasmsLast Updated:November 24, 2021Completed
Condition(s):Advanced Solid TumorLast Updated:August 25, 2021Unknown status
Condition(s):Triple Negative Breast CancerLast Updated:August 7, 2023Completed
Condition(s):Neoplasm, Advanced or MetastaticLast Updated:January 8, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.